United Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent
Overview
United Therapeutics Corporation recently filed a lawsuit under the Hatch-Waxman Act, asserting their ‘793 patent in response to Liquidia’s amendment to its New Drug Application (NDA) to include PH-ILD on the label of YUTREPIA™. This new litigation comes after the ‘793 patent was previously deemed invalid by the Patent Trial and Appeal Board (PTAB).
Details of the Lawsuit
The lawsuit filed by United Therapeutics Corporation alleges that Liquidia’s inclusion of PH-ILD on the YUTREPIA™ label infringes on their ‘793 patent, despite the patent being ruled invalid by the PTAB in the past. This legal battle highlights the complexities and challenges surrounding patent disputes in the pharmaceutical industry.
Implications
The ongoing litigation between United Therapeutics Corporation and Liquidia raises questions about the validity of patents and the potential impact on the market for PH-ILD treatments. It also underscores the competitive nature of the pharmaceutical industry and the importance of intellectual property protection.
Effects on Individuals
For individuals, the outcome of this lawsuit could impact access to PH-ILD treatments and the cost of these medications. Depending on the ruling, patients may see changes in the availability and affordability of YUTREPIA™ and other similar drugs.
Global Impact
From a global perspective, this legal battle sheds light on the complexities of patent law and intellectual property rights in the pharmaceutical industry. The outcome of this case could set a precedent for future disputes and influence how companies approach patent infringement claims on a global scale.
Conclusion
Overall, the lawsuit filed by United Therapeutics Corporation against Liquidia Corporation underscores the importance of protecting intellectual property rights in the pharmaceutical industry. The outcome of this legal battle will have implications for individuals seeking PH-ILD treatments and could have a broader impact on the global pharmaceutical market.